---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-131705"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2024-12-26T23:59:59+00:00"
generated_at: "2026-05-28T23:16:51.144399+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Carisma Therapeutics appoints interim VP of Finance, principal accounting officer

## Summary
- Natalie McAndrew appointed interim VP of Finance effective Jan 1, 2025.
- She will serve as principal financial officer and principal accounting officer.
- Ms. McAndrew is a Senior Director at Danforth Advisors, providing finance and accounting services under a master services agreement.
- Her background includes roles at Apertura Gene Therapy, Baudax Bio, Tmunity Therapeutics, Spark Therapeutics.
- The services agreement with Danforth can be terminated by either party with 30 days cause or 60 days without cause.

## SEC filing metadata
- accession: 0001104659-24-131705
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2024-12-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465924131705/0001104659-24-131705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465924131705/tm2432018d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-131705
- JSON: https://secwatch.observer/filing/0001104659-24-131705.json
- Plain text: https://secwatch.observer/filing/0001104659-24-131705.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.